You are here

Generic Version of Brethine Approved

PHILADELPHIA--(BUSINESS WIRE)--March 29, 2005--Lannett Company, Inc. (Amex:LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA) of Terbutaline Sulfate Tablets 2.5mg and 5 mg. The company expects to commence marketing this product shortly.

Terbutaline Sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema, and is the generic equivalent of Brethine(R) Tablets marketed by Novartis Pharmaceuticals and aaiPharma Inc.

"We are pleased that our product development efforts are beginning to pay dividends with our first product approval thus far in 2005," said Arthur Bedrosian, president of Lannett. "With ten product applications currently pending at the FDA, we look forward to additional approvals this year, further building our product offering."

According to NDC Health, the total U.S. market for Terbutaline Sulfate tablets is approximately $11 million. Currently, there is only one other generic supplier marketing this product.

Source: Lannett Company, Inc.

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds